scholarly journals Immunosuppression Enhances Oncolytic Adenovirus Replication and Antitumor Efficacy in the Syrian Hamster Model

2008 ◽  
Vol 16 (10) ◽  
pp. 1665-1673 ◽  
Author(s):  
Maria A Thomas ◽  
Jacqueline F Spencer ◽  
Karoly Toth ◽  
John E Sagartz ◽  
Nancy J Phillips ◽  
...  
Keyword(s):  
Syrian Hamster ◽  
Oncolytic Adenovirus ◽  
Antitumor Efficacy ◽  
Hamster Model ◽  
Adenovirus Replication

scholarly journals A Tumor-Targeted Replicating Oncolytic Adenovirus Ad-TD-nsIL12 as a Promising Therapeutic Agent for Human Esophageal Squamous Cell Carcinoma

Cells ◽  
2020 ◽  
Vol 9 (11) ◽  
pp. 2438
Author(s):  
Zifang Zhang ◽  
Chunyang Zhang ◽  
Jinxin Miao ◽  
Zhizhong Wang ◽  
Zhimin Wang ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cell Lines ◽  
Squamous Cell ◽  
Syrian Hamster ◽  
Single Agent ◽  
Oncolytic Adenovirus ◽  
Hamster Model

Esophageal squamous cell carcinoma (ESCC) is one of the most lethal cancers in China and existing therapies have been unable to significantly improve prognosis. Oncolytic adenoviruses (OAds) are novel promising anti-tumor drugs and have been evaluated in several cancers including ESCC. However, the antitumour efficacy of the first generation OAds (H101) as single agent is limited. Therefore, more effective OAds are needed. Our previous studies demonstrated that the novel oncolytic adenovirus Ad-TD-nsIL12 (human adenovirus type 5 with E1ACR2, E1B19K, E3gp19K-triple deletions)harboring human non-secretory IL-12 had significant anti-tumor effect, with no toxicity, in a Syrian hamster pancreatic cancer model. In this study, we evaluated the anti-tumor effect of Ad-TD-nsIL12 in human ESCC. The cytotoxicity of Ad-TD-nsIL12, H101 and cisplatin were investigated in two newly established patient-derived tumor cells (PDCs) and a panel of ESCC cell lines in vitro. A novel adenovirus-permissive, immune-deficient Syrian hamster model of PDCs subcutaneous xenograft was established for in vivo analysis of efficacy. The results showed that Ad-TD-nsIL12 was more cytotixic to and replicated more effectively in human ESCC cell lines than H101. Compared with cisplatin and H101, Ad-TD-nsIL12 could significantly inhibit tumor growth and tumor angiogenesis as well as enhance survival rate of animals with no side effects. These findings suggest that Ad-TD-nsIL12 has superior anti-tumor potency against human ESCC with a good safety profile.

The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model

2016 ◽  
Vol 23 (1) ◽  
pp. 239-249 ◽  
Author(s):  
Xiaozhu Li ◽  
Pengju Wang ◽  
Hang Li ◽  
Xuexiang Du ◽  
Mingyue Liu ◽  
...  
Keyword(s):  
T Cell ◽  
Syrian Hamster ◽  
T Cell Responses ◽  
Oncolytic Adenovirus ◽  
Hamster Model ◽  
Cell Responses

scholarly journals Effect of Preexisting Immunity on Oncolytic Adenovirus Vector INGN 007 Antitumor Efficacy in Immunocompetent and Immunosuppressed Syrian Hamsters

2008 ◽  
Vol 83 (5) ◽  
pp. 2130-2139 ◽  
Author(s):  
Debanjan Dhar ◽  
Jacqueline F. Spencer ◽  
Karoly Toth ◽  
William S. M. Wold
Keyword(s):  
Immune Responses ◽  
Syrian Hamster ◽  
Treatment Efficacy ◽  
Adenovirus Vector ◽  
Neutralizing Antibody ◽  
Intratumoral Injection ◽  
Antitumor Efficacy ◽  
Hamster Model ◽  
The Difference

ABSTRACT Immune responses against adenovirus (Ad) vectors pose a possible concern for the outcome of treatment efficacy. To address the role of preexisting immunity in oncolytic Ad vector antitumor efficacy following intratumoral injection of vector as well as tumor-to-tissue spread of the vector, we employed the Syrian hamster model. These animals are immunocompetent, and their tumors and tissues are permissive for replication of Ad type 5 (Ad5). We used the adenovirus death protein-overexpressing Ad5-based vector INGN 007. Subcutaneous tumors were established in groups of hamsters that were or were not immunized with Ad5. Half of the hamsters in these groups were immunosuppressed with cyclophosphamide. For all groups, tumors injected with INGN 007 grew significantly more slowly than those injected with buffer. Under immunocompetent conditions, there was no significant effect of preexisting immunity on vector antitumor efficacy. Soon after the tumors in naïve animals were injected with vector, the hamsters developed neutralizing antibody (NAb) and the difference in NAb titers between the naïve and immunized groups diminished. Under immunosuppressed conditions, preexisting NAb did significantly reduce vector efficacy. Thus, NAb do reduce vector efficacy to some extent, but immunosuppression is required to observe the effect. Regarding vector toxicity, there was spillover of vector from the tumor to the liver and lungs in naïve immunocompetent hamsters, and this was nearly eliminated in the immunized hamsters. Thus, preexisting immunity to Ad5 does not affect INGN 007 antitumor efficacy following intratumoral injection, but immunity prevents vector spillover from the tumor to the liver and lungs.

scholarly journals Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer

Surgery ◽  
2015 ◽  
Vol 157 (5) ◽  
pp. 888-898 ◽  
Author(s):  
Christopher J. LaRocca ◽  
Joohee Han ◽  
Tatyana Gavrikova ◽  
Leonard Armstrong ◽  
Amanda R. Oliveira ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Interferon Alpha ◽  
Syrian Hamster ◽  
Oncolytic Adenovirus ◽  
Hamster Model

Effect of intestinal alkalinization on irinotecan (CPT-11)-induced diarrhea in the golden Syrian hamster model

2001 ◽  
Vol 120 (5) ◽  
pp. A613-A613
Author(s):  
T IKEGAMI ◽  
P LATHAM ◽  
K KOBAYASHI ◽  
K ARIMORI ◽  
B BOUSCAREL
Keyword(s):  
Syrian Hamster ◽  
Hamster Model ◽  
Golden Syrian Hamster
Sign in / Sign up

Export Citation Format

Share Document